母婴死于惰性:亟需建立产科药物开发协作框架
本文指出产科综合征是全球年轻女性及其婴儿死亡和发病的常见原因,但治疗手段远落后于其他医学领域。药物开发面临安全性担忧、定义不清、监管路径高风险、病理生理理解不足及伦理审查障碍等挑战。作者呼吁各方共同投入并建立伦理、立法和指南框架,以推动安全有效产科药物的研发。
要点
- 产科综合征治疗手段严重不足,药物开发面临多重障碍。
- 安全性担忧、定义不清和高风险监管路径降低企业投资意愿。
- 需建立伦理、立法和指南框架并推动多方协作。
核心结论
- 产科并发症治疗药物开发严重滞后,亟需建立协作框架以推动安全有效疗法的研发。
研究设计与样本
- 本文为针对产科药物研发挑战的综述性论述,未报告系统检索范围或样本量。
主要发现
- 产科综合征是全球年轻女性及其婴儿死亡和发病的常见原因,但治疗手段相比其他医学领域发展不足。
- 药物开发挑战包括对母婴安全的担忧、疾病定义不清、监管审批路径高风险且投资回报无保障。
- 对产科综合征病理生理理解不足及其人类妊娠独特性限制了临床前转化和去风险策略。
- 胎儿安全性监测有限,难以捕捉早期产前不良反应。
- 伦理审查委员会不愿批准孕妇纳入试验,且产科缺乏监管指导使临床开发路径不可预测。
临床怎么用
- 需对创新疗法研究做出实质性承诺和投资,同时建立有利的伦理、立法和指南框架。
- 应让患者、夫妇和临床医生等所有利益相关方共同参与,以统一预期并推进该领域进展。
局限性
- 本文为论述性文章,未提供系统检索策略或原始研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obstetrical complications, often referred to as the "great obstetrical syndromes," are among the most common global causes of mortality and morbidity in young women and their infants. However, treatments for these syndromes are underdeveloped compared with other fields of medicine and are urgently needed. This current paucity of treatments for obstetrical complications is a reflection of the challenges of drug development in pregnancy. The appetite of pharmaceutical companies to invest in research for obstetrical syndromes is generally reduced by concerns for maternal, fetal, and infant safety, poor definition, and high-risk regulatory paths toward product approval. Notably, drug candidates require large investments for development with an unguaranteed return on investment. Furthermore, the discovery of promising drug candidates is hampered by a poor understanding of the pathophysiology of obstetrical syndromes and their uniqueness to human pregnancies. This limits translational extrapolation and de-risking strategies in preclinical studies, as available for other medical areas, compounded with limited fetal safety monitoring to capture early prenatal adverse reactions. In addition, the ethical review committees are reluctant to approve the inclusion of pregnant women in trials, and in the absence of regulatory guidance in obstetrics, clinical development programs are subject to unpredictable regulatory paths. To develop effective and safe drugs for pregnancy complications, substantial commitment, and investment in research for innovative therapies are needed in parallel with the creation of an enabling ethical, legislative, and guidance framework. Solutions are proposed to enable stakeholders to work with a common set of expectations to facilitate progress in this medical discipline. Addressing this significant unmet need to advance maternal and possibly perinatal health requires the involvement of all stakeholders and specifically patients, couples, and clinicians facing pregnancy complications in the dearth of appropriate therapies. This paper focused on the key pharmaceutical research and development challenges to achieve effective and safe treatments for obstetrical syndromes.
引用
- Roset Bahmanyar E, Out HJ, van Duin M, et al. Women and babies are dying from inertia: a collaborative framework for obstetrical drug development is urgently needed. Am J Obstet Gynecol. 2021. PMID: 34215353. doi:10.1016/j.ajog.2021.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。